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Context: Todate,penetrance figures formedullary thyroidcancer (MTC) for variants in rearrangedduring
transfection (RET) have been estimated from families ascertained because of the presence of MTC.
Objective: To gain estimates of penetrance, unbiased by ascertainment, we analyzed 61 RET
mutations assigned as disease causing by the American Thyroid Association (ATA) in population
whole-exome sequencing data.
Design: For the61RETmutations,weusedanalyses of theobservedallele frequencies in;51,000 individuals
fromtheExomeAggregationConsortium(ExAC)databasethatwerenotcontributedviaTheCancerGenome
Atlas (TCGA; non-TCGA ExAC), assuming lifetime penetrance for MTC of 90%, 50%, and unbounded.
Setting: Population-based.
Results: Ten of 61 ATA disease-causing RET mutations were present in the non-TCGA ExAC
population with observed frequency consistent with penetrance for MTC of .90%. For p.Val804Met,
the lifetime penetrance for MTC, estimated from the allele frequency observed, was 4% [95%
confidence interval (CI), 0.9% to 8%].
Conclusions: Based on penetrance analysis in carrier relatives of p.Val804Met-positive cases of MTC,
p.Val804Met is currently understood to have high-lifetime penetrance for MTC (87% by age 70),
albeit of later onset of MTC than other RETmutations. Given our unbiased estimate of penetrance
for RET p.Val804Met of 4% (95% CI, 0.9% to 8%), the current recommendation by the ATA of
prophylactic thyroidectomy as standard for all RET mutation carriers is likely inappropriate. (J Clin
Endocrinol Metab 103: 4275–4282, 2018)
Multiple endocrine neoplasia type 2 (MEN2) wasfirst recognized in the mid- to late-1960s as a
pleomorphic cancer-susceptibility syndrome, characterized
by a high risk of medullary thyroid cancer (MTC) (1–3).
Clinically distinct subtypes of MEN2 were subsequently
described with MEN2A, characterized by MTC plus
pheochromocytoma and parathyroid disease; MEN2B
featuring MTC plus marfanoid habitus, benign oral, and
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submucosal tumors; and familial MTC (FMTC) withMTC
alone. In 1993, the rearranged during transfection (RET)
protooncogene was definitively identified as the gene un-
derlying MEN2 (4, 5), and germline mutations have sub-
sequently been detected in nearly all families with MEN2A,
MEN2B, and FMTC, with emergence of a distinct pattern of
genotype-phenotype correlation (Table 1).More recently, the
American Thyroid Association (ATA) categorized RET
mutations based on age-related penetrance of MTC. The
2009 ATA guidance adopted classes A through D (with D as
the most severe); in the 2015 revisions, they were updated to
“moderate”, “high” and “highest” risk of MTC, with ac-
cordant guidance on timing of prophylactic thyroidectomy
for unaffected RET mutation carriers (Table 1) (6, 7).
As typical for rare Mendelian disease, studies correlating
mutational frequencies ofRETwithdiseasemanifestationof
MTC/MEN2are based on clinical case series, ascertainment
of which is necessarily based on their phenotype. Only
through the studying of a population ascertained agnostic to
phenotype can unbiased estimates of disease penetrance
for a given variant be calculated. Whereas data from large-
scale sequencing of “true” population controls are not yet
available, unbiased estimates of cancer penetrance can be
derived from sequencing data aggregated from cohorts of
individuals with “common complex” conditions unrelated
to cancer, such as hypertension, autoimmune disease, and
diabetes (8–11). Here, we present analysis of “population”
sequencing data from ;51,000 individuals for the 61 RET
mutations designated as disease causing by the ATA.
Materials and Methods
Identification of pathogenic RET mutations
RET protein alterations, designated as disease causing
(pathogenic) by the ATA, were identified within the published
guidelines, and matching variants were retrieved from ClinVar,
along with their corresponding changes at the nucleotide level
(6, 7, 12, 13). We identified a total of 61 different pathogenic
RET single nucleotide variants, corresponding to 53 different
protein alterations at 24 different residues (Tables 1 and 2).
Population dataset
We used a subsetted version of the Exome Aggregation
Consortium (ExAC)database that had excluded individuals from
The Cancer Genome Atlas (TGCA; non-TCGA ExAC; release
0.3.1) to obtain estimates of the frequency of pathogenic RET
mutations in common complex disease cohorts not related to
cancer (8). This subset of ExAC comprises;51,000 individuals,
the vast majority of which are aged between 40 and 70 years
at the time of ascertainment (10), with a male-to-female ratio of
1.3:1.
Calculation of “expected” allele counts
With the use of the methods of Whiffin et al. (14), we
calculated the maximum number of mutant alleles that we
would expect to observe in the non-TCGA ExAC data for a
pathogenic RET mutation. In brief, this method leverages the
logic that a fully penetrant allele cannot be more common than
the disease it causes. Therefore, for a given disease/gene, the
maximum credible population allele frequency can be calcu-
lated by the multiplication of lifetime risk (expressed as one in
n) by total allelic contribution (expressed as a value between
zero and one), divided by penetrance (expressed as a value
between zero and one), multiplied by two (reflecting the
diploid human genome). The maximum tolerated allele count
is then determined based on the population size at a given level
of confidence. When assigning a value to each parameter used
in the model, we selected the most conservative estimate of the
range represented in the literature, i.e., the highest estimates for
lifetime risk and total allelic contribution and the lowest es-
timate for penetrance. The application of values for lifetime
risk of disease and total allelic contribution that are higher
than the true underlying values will overestimate the expected
allele count. Likewise, the underestimation of penetrance will
also overestimate the expected allele count. P values were
Table 1. Genotype-Phenotype Correlations in MEN2
ATA Risk
Levela RET Mutationsb MEN2 Subtype Age of MTC
ATA Recommendations for
Thyroidectomya
Moderate
(ATA-MOD)
p.Gly533Cys; p.Lys603Glu; p.Tyr606Cys;
p.Cys609Arg/Gly/Phe/Ser/Tyr;
p.Cys611Arg/Gly/Phe/Ser/Trp/Tyr;
p.Cys618Arg/Gly/Phe/Ser/Tyr;
p.Cys620Arg/Gly/Phe/Ser/Trp/Tyr;
p.Cys630Arg/Phe/Ser/Tyr; p.Asp631Tyr;
p.Lys666Glu; p.Glu768Asp; p.Asn777Ser;
p.Leu790Phe; p.Val804Leu/Met; p.Arg833Cys;
p.Arg844Gln; p.Ser891Ala; p.Arg912Pro
FMTC and MEN2A .5 y In childhood (by 5 or 10 y) or
adulthood or when serum
calcitonin level becomes
elevated
High (ATA-H) p.Cys634Arg/Gly/Phe/Ser/Trp/Tyr; p.Ala883Phe MEN2A ,5 y At or before 5 y, based on
calcitonin serum levels
Highest
(ATA-HST)
p.Met918Thr MEN2B ,1 y First y or first mos of life
Abbreviation: ATA, American Thyroid Association.
aAs per the revised ATA 2015 guidelines (7).
bMutations annotated using Reference Sequence accession NM_020975.
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calculated for observed vs expected values using a one-way x2
test. The P value threshold for significance was corrected for
performing 61 tests (P value threshold = 8.2 3 1025). We
define in the following sections how the parameters modeled to
calculate expected allele counts for application were derived.
Lifetime risk
The reported lifetime risk of MTC varies widely: Orphanet
Encyclopedia suggests a lifetime risk of 1:14,300 (15). Reported
incidence ofMTC varies by sex and population. The two largest
populations in ExAC are the following: (1) Utah residents with
Northern and Western European ancestry and (2) British in
England and Scotland, which comprise 24% and 17% of total
individuals in ExAC, respectively (10). In the United States, the
lifetime risk of thyroid cancer is estimated to be one in 167 men
and one in 56women, with 1% to 2%comprising themedullary
subtype (7). With the use of the upper bound of these estimates,
this equates to a lifetime risk ofMTC in the United States of one
in;8300 for men and one in;2700 for women (one in;4100
overall). In the United Kingdom, the lifetime risk of thyroid
cancer is estimated to be one in 480 in men and one in 180 in
females (16), with#8%of themedullary subtype (17, 18).With
the use of the upper bound of these estimates, this equates to a
lifetime risk of MTC in the United Kingdom of one in 6000 in
men and one in 2250 in women (approximately one in 3300
overall). For the purpose of this study, we use a conservatively
high (common) estimate of one in 3000 for the risk of MTC
across a UK/US population of Northern andWestern European
ancestry [which is far higher and therefore, more conservative
than the underlying frequency of 1:14,300, suggested by the
Orphanet Encyclopedia (15)]. We have also not corrected for
the sex disparity in ExAC (which would equate to a predicted
lower average lifetime risk as a result of the higher proportion of
men to women in this cohort).
Total allelic contribution
Total allelic contribution is a function of both genetic and
allelic heterogeneity. Genetic heterogeneity refers to the maxi-
mum proportion of a disease attributable to a single gene,
whereas allelic heterogeneity refers to the maximum proportion
of pathogenic variation within a gene attributable to a specific
single allele. We used data from the largest recent published
dataset from systematic data collection from a 20-year Italian
single center experience of RET testing, which included 1556
subjects (19). In this series, ;8% of MTC cases have a family
history of MTC (with RET mutations detected in 98% of
multiplexMTC families), andRETmutations are detected in an
additional ;7% of “seemingly” sporadic MTC cases (19, 20).
With the use of an upper range of the sum of these two elements,
we apply to the model a conservatively high estimate for genetic
heterogeneity of 0.20.
In this series, the most frequently detected mutation was seen
in 31/139 probands (22.3%, p.Val804Met), with the second-
most populous pathogenic mutation detected in 17/139,
(12.2%, p.Cys634Arg) (19). With the use of an upper range
on these estimates, we defined the maximum allelic heteroge-
neity for a pathogenic mutation in RET to be 0.25. Thus, the
highest total allelic contribution for a single RET mutation to
MTC is 0.05 (0.25 3 0.20).
Penetrance
Most literature on pathogenic germline RET mutations
describes near-complete lifetime penetrance for MTC, with the
Table 2. RET Mutation Allele Counts in Non-TCGA ExAC
RET Mutationa
Non-TCGA ExACb 90% Penetrance 50% Penetrance
Allele
Count
Alleles
Observed
Minor Allele
Frequency
Alleles
Expectedc P Valued
Alleles
Expectedc P Valued
ATA moderate-risk level (MOD)
c.1799G . A:p.Arg600Gln 80,494 3 3.73 3 1025 2 4.79 3 1021 3 1.00 3 10°
c.2330A . G:p.Asn777Ser 105,944 1 9.44 3 1026 3 2.48 3 1021 4 1.34 3 1021
c.2370G . C:p.Leu790Phe 105,414 1 9.49 3 1026 3 2.48 3 1021 4 1.34 3 1021
c.2370G . T:p.Leu790Phe 105,414 2 1.90 3 1025 3 5.64 3 1021 4 3.17 3 1021
c.2410G . A:p.Val804Met 55,798 11 1.97 3 1024 2 1.96 3 10210 3 3.86 3 1026
c.2410G . T:p.Val804Leu 55,798 1 1.79 3 1025 2 4.79 3 1021 3 2.48 3 1021
c.2497C . T:p.Arg833Cys 104,240 2 1.92 3 1025 3 5.64 3 1021 4 3.17 3 1021
c.2531G . A:p.Arg844Gln 105,686 4 3.78 3 1025 3 5.64 3 1021 4 1.00 3 10°
c.2735G . C:p.Arg912Pro 106,202 1 9.42 3 1026 3 2.48 3 1021 4 1.34 3 1021
ATA high-risk level (H)
c.1900T . C:p.Cys634Arg 106,030 1 9.43 3 1026 3 2.48 3 1021 4 1.34 3 1021
c.1901G . T:p.Cys634Phe 106,036 1 9.43 3 1026 3 2.48 3 1021 4 1.34 3 1021
aFifty ATA pathogenic RET single nucleotide variants, not observed in non-The Cancer Genome Atlas Exome Aggregation Consortium (TCGA ExAC),
collapsed by residue: moderate-risk level: p.G533C, p.K603E, p.T606C, p.C609S/R/G/T/F, p.C611S/R/G/T/F/W, p.C618S/R/G/T/F/W, p.C620S/R/G/T/
F/W, p.C630S/R/T/F, p.D631T p.K666E, p.E768D, p.E768D, p.Val804L, p.S891A; high-risk level: p.C634S/G/T/W, p.A883F; highest-risk level: p.E805K,
p.T806C, p.M918T. Annotated using Reference Sequence accession NM_020975.
bNon-TCGA ExAC data for;51,000 individuals. The age of individuals included in this dataset, at the time of ascertainment, ranges from 18 to 85, with
most individuals aged 40 to 70 y.
cCalculated using the method of Whiffin et al. (14). MTC lifetime risk estimated at one in 3000, genetic heterogeneity is estimated at 20%, allelic
heterogeneity at 25%, and powered for penetrance .90% and .50%.
dOne-way x2 test to compare observed and expected values using a Bonferroni corrected P value threshold for significance for performing 61 tests (P value
threshold = 8.2 3 1025).
doi: 10.1210/jc.2017-02529 https://academic.oup.com/jcem 4277
D
ow
nloaded from
 https://academ
ic.oup.com
/jcem
/article-abstract/103/11/4275/4951497 by St G
eorge's U
niversity of London user on 26 February 2019
assumption only of differences in age-related penetrance for
mutations in different ATA subgroups (7). To explore pene-
trance for pathogenic germline RET mutations in this study,
expected allele counts were calculated under two models: (1) the
firstmodel assuming near-complete lifetime penetrance (90%) and
(2) a second model assuming reduced lifetime penetrance (50%).
Calculating penetrance for RET p.Val804Met
We went on to explore penetrance for RET p.Val804Met,
using the samemodel but fixing the allele count observed in non-
TCGA ExAC as the maximum credible population allele fre-
quency. We first applied our best baseline values derived from
the literature for lifetime risk of MTC (one in 3000) and total
allelic contribution (0.203 0.25) to generate the best estimate of
penetrance for RET p.Val804Met compatible with the allele
count observed in non-TCGA ExAC. We went on to perform
sensitivity testing on this penetrance estimate by applying different
estimates of lifetime risk ofMTC (one in 1000, one in 3000, one in
5000), genetic heterogeneity (0.20, 0.30, 0.40), and allelic het-
erogeneity (0.25, 0.35, and 0.45; Fig. 1), generating 95% confi-
dence intervals (CIs) based on the observed allele frequency.
Results
Frequency of pathogenic RET mutations in
non-TCGA ExAC
Of the 61 pathogenic RET mutations documented in
the ATA guidelines (Table 1), 11 were present in in-
dividuals in the non-TCGA ExAC population cohort.
Fifty of the 61 mutations were not detected at all in this
population cohort. Of the 11 pathogenic RETmutations
present in individuals in non-TCGA ExAC, nine were in
the moderate risk category, and two were in the high risk
category (Table 2).
With the use of the conservative baseline estimates from
the literature formodel parameters (MTC lifetime risk: one
in 3000, genetic heterogeneity: 20%, allelic heterogeneity:
25%), only c.2410G . A p.Val804Met had an observed
allele count that significantly exceeded that which would
be expected if the penetrance for MTC for this mutation
was$90%, (Table 2; observed allele count = 11, expected
allele count = 2,P = 1.963 10210). The difference between
observed and expected allele counts for p.Val804Met
remained significant, even when applying a model based
on a substantially reduced penetrance of 50% (expected
allele count = 3,P = 3.863 1026).Of note, theminor allele
frequency (MAF) for p.Val804Met was consistent across
the four main subpopulations constituting the non-TCGA
ExAC: non-Finnish Europeans MAF = 0.000175 [ob-
served (O) = 5, expected (E) = 2, P = 3.393 1022]; South
Asian MAF = 0.000260 (O = 3, E = 1 P = 4.55 3 1022);
Latino MAF = 0.000358 (O = 2, E = 0); and East Asian
MAF = 0.00027 (O = 1, E = 0; Table 2). The MAF for p.
Val804Met in the larger Genome Aggregation Database
(MAF = 0.00014, from 129,886 individuals) was con-
sistent with that in the non-TCGAExAC (MAF = 0.0002).
Observed allele counts for all 60 other pathogenic
RETmutations were consistent with our baseline model,
assuming a penetrance $90%.
Figure 1. Penetrance for RET p.Val804Met as a function of genetic heterogeneity, allelic heterogeneity, and lifetime risk of MTC. (A) Total allelic
contribution (x-axis) is the product of the genetic heterogeneity, multiplied by allelic heterogeneity [e.g., a genetic heterogeneity of 20% and an
allelic heterogeneity of 25% gives a total allelic contribution of 5% (or 0.05)]. Penetrance estimates were generated using lifetime risk under
three scenarios: a lifetime risk, one in 3000 [a conservative estimate derived from a lifetime risk of MTC in the United States/United Kingdom
(green line) and sensitivity testing using lower and higher estimates: one in 5000 (blue line) and one in 1000 (red line). Dashed lines and shading
indicate 95% confidence intervals (CIs). (B) Point estimates of penetrance are shown by lifetime risk of MTC of one in 3000 (green fill), one in
5000 (blue fill), one in 1000 (red fill) with literature-derived estimates for genetic heterogeneity (25%), and allelic heterogeneity (20%) and
sensitivity testing using higher estimates (35% and 45%, 30% and 40%, respectively).
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Estimates for penetrance of p.Val804Met
With the use of the conservative, best baseline esti-
mates from the literature for model parameters (MTC
lifetime risk: one in 3000, genetic heterogeneity: 20%,
allelic heterogeneity: 25%), the observed frequency of
p.Val804Met in non-TCGA ExAC is consistent with a
lifetime penetrance of MTC of 4% (95% CI, 0.9% to
8%). In sensitivity testing, the application of parameter
estimates hugely exceeding those consistent with existing
data (population incidence: one in 1000, genetic het-
erogeneity: 40%, allelic heterogeneity: 45%), the population
frequency observedwas consistentwith a penetrance of only
46% (95% CI, 1% to 82%; Fig. 1).
Discussion
Here, we present population data for p.Val804Met that
shows a frequency greater than fivefold higher than that
of any other pathogenic RET mutation. For all other
pathogenic RET mutations, the observed frequency is
consistent with a lifetime penetrance of MTC of .90%,
whereas forRET p.Val804Met, the observed frequency is
not even consistent with a lifetime penetrance of 50% (P =
3.863 1026; Table 1). We go on to demonstrate that the
observed frequency of p.Val804Met in non-TCGAExAC
supports a lifetime penetrance of MTC for p.Val804Met
of 4% (95% CI, 0.9% to 8%). Even allowing for a much
higher lifetime risk of MTC, e.g., one in 1000, the ob-
served frequency is only compatible with a lifetime
penetrance forMTCof 12% (95%CI, 3% to 23%).With
sensitivity testing, using this unrealistically high estimate
of lifetime risk of MTC (one in 1000), in combination
with similarly implausible estimates of allelic heteroge-
neity (45%) and genetic heterogeneity (40%), the ob-
served frequency of p.Val804Met still only equates to a
penetrance for MTC of 46% (95% CI, 1% to 82%).
Studies of detection rates for RET mutations vary
widely depending on inclusion criteria for individuals/
families tested, and variable distributions of different
RET mutations have been reported from studies of dif-
ferent geographic regions (19–24). Between-study esti-
mates may reflect genuine differences, as a result of
disparities in ethnicity and/or founder effects, but may
also reflect artifacts from incomplete testing of the full
RET gene, patient recruitment criteria, and reporting of
results. Therefore, we used, for our baseline parameters,
estimates based on the largest single center experience
reported, inwhich systematic testing of the relevant exons
had been undertaken (19).
The methodology used in the current study does not
explicitly take into account age at disease diagnosis or the
reduced life expectancy for individuals diagnosed with
MTC. It is plausible that a population dataset comprising
individuals with common conditions ascertained in
middle age would be “de-enriched” for individuals with
early-onset, life-limiting disease (survival bias). Likewise,
our model assumes that individuals who have developed
treatable MTC or have had preventative surgery would
be proportionately sampled into the ExAC cohorts
compared with the reference population: in practice, it is
likely that these individuals would likewise be under-
represented (selection bias). However, any such survival
bias or selection bias would serve to de-enrich the ExAC
cohorts formutations causative ofMTC, only resulting in
our calculations of penetrance presented being over-
estimates. Finally, inclusion in the ExAC cohort would
not be influenced by MTC arising later in life (i.e., after
inclusion in the whole genome sequencing/whole exome
sequencing cohort); hence, later disease would not bias
our estimates of penetrance.
Population stratification may cause confounding ef-
fects by the skewing of observed allele frequency, for
example, as a result of ethnic population-specific ef-
fects from founder mutations. The broad makeup of the
ExAC series from several outbred subpopulations makes
this unlikely. Furthermore, the elevated frequency of
p.Val804Met is observed across the four major sub-
populations of ExAC in this study. In addition, there is
consistency of MAF between ExAC and the larger re-
cently released Genome Aggregation Database dataset,
negating a substantial contribution from“chance” sampling
variation (type 1 error).
p.Val804Met is one of the most commonly reported
pathogenic mutations inRET.However, the literature, to
date, for p.Val804Met is mixed regarding phenotypic
correlates, as well as overall and age-related penetrance.
Most typically associatedwith the FMTC spectrum, there
are reports of p.Val804Met associated with pheochro-
mocytomatous but also papillary thyroid cancer. There
are reports in the literature of p.Val804Met detected in
high-penetrance families, as well as very early-onset cases
(25–27). A number of studies have reported C cell hy-
perplasia as a ubiquitous finding in prophylactically re-
moved thyroid glands from “unaffected” carriers of
p.Val804Met (25–27). The only numeric estimate for
penetrance for p.Val804Met published to date has been
from Rich et al. (28), who report penetrance of RET p.
Val804Met forMTC to age 70 as 87% (95%CI, 71% to
94%), with the median age of detection of MTC at 54
years. This is far and away the largest analysis of its kind
published to date, including 160 individuals identified
with p.Val804Met via familial cascade genetic screening
alone. Therefore, this study would be credited for ro-
bustness of methodology, insofar as index cases of MTC
were excluded to minimize upward bias in estimates of
penetrance. This study confirmed thatRET p.Val804Met
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was indeed typically associated with later onset of MTC
than typical for other pathogenic germline RET muta-
tions but asserted that albeit of later onset, penetrance for
disease was nevertheless near complete (28). Therefore,
this analysis was seen to be consistent with several earlier
descriptive reports in the literature, suggesting that RET
p.Val804Met must have a different penetrance profile for
MTC compared with the other RET mutations that
typically cause MTC in childhood (26, 29).
Occurrence of two germlineRETmutations in tandem
on the same allele have been described, with p.Val804Met
reported in tandem with p.Gln781Arg, p.Glu805Lys,
p.Tyr806Cys, or p.Ser904Cys (30). Such tandem ge-
notypes have been demonstrated in vitro as having a
higher transforming ability comparedwith their singleton
counterparts (31). Commensurate with this, these tan-
dem genotypes are associated clinically with more ag-
gressive early-onset MTC and were assigned highest risk
designation by the ATA. Notably, the two-tier/single-
exon approach to mutational analysis, previously used
in clinical practice and earlier studies, could have been at
risk for failure to detect a second mutation in a different
exon (e.g., p.Ser904Cys). This raises the possibility that
occasional individuals/families with a tandem genotype
(and accordingly, more severe phenotype) may have er-
roneously been ascribed as just having p.Val804Met.
This could potentially contribute (likely in small part) to
explaining some of the apparently variable penetrance
and expressivity that has been widely reported in the
literature for p.Val804Met (25, 26). Of note, none of the
“second”mutations constituting these tandem genotypes
were detected in our population dataset; therefore, con-
sideration of tandem genotypes is not relevant to the
penetrance estimates that we present here for p.Val804Met.
Interestingly, homozygosity for p.Val804Met has been
detected in individuals undergoing RET testing for
seemingly sporadic MTC (32, 33), an observation en-
tirely consistent with the comparatively high-population
frequency for p.Val804Met that we describe.
The history in the literature, combined with the data
we present here, demonstrates beautifully the influence of
ascertainment bias on the published estimates of pene-
trance with which we currently manage our patients.
Penetrance for MTC of RET p.Val804Met is likely
substantially influenced by additional modifier factors,
the “dose” of which is distributed across the population.
Early testing of RET was typically focused on probands
with more severe phenotypes (MEN2A or MEN2B),
young-onset MTC, and/or a family history of disease.
Hence, such analyses would generate estimates reflecting
the “combined” penetrance of p.Val804Met RET plus a
high dose of modifying factors ipso facto present in those
with severe and/or familial disease. Even when the RET
mutations are ascertained from an “unselected” series of
MTC, these individuals (and therefore, their close rela-
tives) will necessarily have a dose of modifier factors
substantially above the population average. The pop-
ulation data presented here (unbiased in its ascertainment
by phenotype) reflect that the distribution of modifying
factors across the general population is such that only
;4% of individuals have a sufficient dose of modifiers,
such that they will develop MTC when carrying RET
p.Val804Met. Observed familial clustering supports
existence of p.Val804MetRETmodifying factors that are
“shared”within families. Whereas these factors are most
likely to be heritable (genetic), shared environmental
(“household”) factors may also be relevant.
The observation in control data of a frequency of
p.Val804Met, which is approximately fivefold higher
than that of any of the other ATA moderate-risk
RET mutations, is clear evidence that the penetrance
of p.Val804Met must be significantly lower than for
other mutations. Indeed, our analyses, based on best es-
timates of genetic, allelic heterogeneity, and lifetime risk of
MTC, suggest that the penetrance for p.Val804Met may
be ,5%. Increasing affordability and throughput of
next-generation sequencing technologies have dramati-
cally expanded the volume and reduced the thresholds for
genetic testing; RET is included on several multigene
cancer panels widely tested in oncology and familial
cancer clinics. Furthermore, RET is one of the 59 genes
for which the American College of Medical Genetics and
Genomics recommends reporting as a secondary finding
(i.e., reporting in individuals with no relevant history of
cancer in whom whole exome sequencing or whole ge-
nome sequencing is undertaken for unrelated indications)
(34, 35). We are just dipping our feet into the oncoming
tidal wave of massive expansion in genomic testing,
which will be undertaken in contexts increasingly distant
from those classic “high-penetrance” multiplex families—
analyses of which underpin our current penetrance data.
Prophylactic surgery in childhood or young adulthood
can be associated with substantial immediate and long-
term morbidity with a requirement for lifelong thyroid
replacement therapy (7).
The ATA currently recommends prophylactic thy-
roidectomy for allRETmutation carriers, stating, “…the
question is not whether prophylactic thyroidectomy
should be performed in patients with hereditary MTC,
but at what age?” Whereas prophylactic thyroidectomy
in early childhood (,5 years) is recommended un-
equivocally for children carrying mutations catego-
rized as high and highest risk, the recommendations
are less didactic for moderate-risk mutations, such as
p.Val804Met. However, because of (1) the challenges of
long-termmonitoring of serum calcitonin in combination
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with (2) recognition of MTC as an aggressive cancer, only
curable if diagnosed when still intrathyroidal, the ATA
currently cautions that “…there are significant risks in
delaying surgery in family members who have inherited a
mutatedRET allele, regardless of the patient’s age onemust
balance the risks of thyroidectomy against the possibility
that the thyroidectomywill be incurable if it is delayed” (7).
We would suggest that the overall emphasis within
ATA recommendations on thyroidectomy, as being
prophylactic (i.e., precedingmanifestation of disease) and
as ultimately “inevitable” for all RET mutation carriers,
should be better clarified. Inevitable prophylactic surgery
may be a reasonable presumptivemodel for the carriers of
most RETmutations who have close relatives affected by
disease.However, for individuals withRET p.Val804Met,
ascertained through population-based testing [i.e., with
no (or an only distant) family history of disease], truly
prophylactic thyroidectomy is likely inappropriate. Based
on the data we present and cognizant of the rapidly
expanding context of testing in the new “genomic” era,
we recommend urgent review by the ATA. In particular,
consideration should be given to (1) p.Val804Met-
specific management guidance and (2) clinical guidance
by context of ascertainment, including explicit recom-
mendation for surveillance with surgery, reflexive only
when there is evidence of emerging disease (36).
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